GLP-1 Drugs Like Wegovy, Ozempic Potentially Linked to Blinding Disease
A study suggests a potential link between GLP-1 drugs like semaglutide and a rare blinding disease called NAION in patients with diabetes or obesity. Further research is needed to clarify this association.
Read original article
A recent study suggests a potential link between the GLP-1 drugs semaglutide, found in Ozempic and Wegovy, and a rare blinding disease called non-arteritic anterior ischemic optic neuropathy (NAION). The research indicates that patients with type 2 diabetes or obesity who take semaglutide may have an increased risk of developing NAION compared to those on non-GLP-1 medications. However, the study does not establish a direct causal relationship between the drug and the condition. Experts emphasize the need for further research to better understand this association. NAION is a rare condition causing sudden blindness in one eye due to reduced blood flow to the optic nerve. Patients and healthcare providers are advised to weigh the risks and benefits of medications like semaglutide based on individual circumstances and medical history. While the findings are significant, they do not definitively prove a danger associated with these drugs, highlighting the importance of ongoing monitoring and research in this area.
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
Rare form of eye stroke that causes blindness now linked to Ozempic and Wegovy
A study links Ozempic and Wegovy to increased risk of rare blindness (NAION) in diabetes and obesity patients. While causation isn't confirmed, caution and consultation with healthcare providers are advised. Novo Nordisk prioritizes patient safety.
3 commentsI made my comment about dependency on these class of drugs a while ago on hacker news but I’d love to see a regimented system that helps patients eventually get off of these drugs or otherwise it seems like we’re trading one con for another (albeit much lesser).
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
Rare form of eye stroke that causes blindness now linked to Ozempic and Wegovy
A study links Ozempic and Wegovy to increased risk of rare blindness (NAION) in diabetes and obesity patients. While causation isn't confirmed, caution and consultation with healthcare providers are advised. Novo Nordisk prioritizes patient safety.